Mucormycosis medications: a patent review.
Mohd ImranAhmed Subeh AlshrariMohammad TauseefShah Alam KhanShuaibu Abdullahi HuduAbida KhanPublished in: Expert opinion on therapeutic patents (2021)
Mucormycosis has few available treatments, including amphotericin-B, isavuconazonium sulfate, posaconazole, or their combination. A few anti-mucormycosis medicines are under clinical development. The exact burden of mucormycosis is unknown, but it is expected to be higher than the reported cases because of mucormycosis epidemiological changes. This patent review has shown that scientists are progressing toward developing a new treatment for mucormycosis in the form of new chemical compounds, new drug combinations, and dosage forms, vaccines, plant products, drug repurposing, and derivatives of the biomolecules. This progress is encouraging to fight this devastating illness.